Observational Study
Copyright ©The Author(s) 2023.
World J Clin Oncol. Jun 24, 2023; 14(6): 215-226
Published online Jun 24, 2023. doi: 10.5306/wjco.v14.i6.215
Table 1 The sample, n (%)

Whole sample, n = 217
mEHT, n = 89
No-mEHT, n = 128
P value1
MedianRangeMedianRangeMedianRange
Age (yr)6734-896438-826934-89NS
Student’s test for proportions
M1225658656450NS
F954431356450NS
Metastatic14265707972560.004
Previous chemotherapy13663687668530.005
Previous Radiotherapy1051197NS
Current chemotherapy type
Gemcitabine/oxaliplatin763534384233NS
Gemcitabine622926293628NS
Gemcitabine/abraxane39189103023NS
Gemcitabine/5-fluorouracil524411NS
Gemcitabine/cisplatin1052286NS
Gemcitabine/Nab-paclitaxel210022NS
FOLFIRINOX521143NS
Other1055654NS
None848900NS
Site of metastases(N = 235)(N = 132)(N = 103)
Liver1325770536361NS
Peritoneum552335272019NS
Lymph nodes371622171515NS
Other1045455NS
Table 2 Tumor response, n (%)

mEHT
n = 87
no-mEHT
n = 111
P value
PR394527240.0018
SD445150450.8430
PD443431< 0.001

  • Citation: Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol 2023; 14(6): 215-226
  • URL: https://www.wjgnet.com/2218-4333/full/v14/i6/215.htm
  • DOI: https://dx.doi.org/10.5306/wjco.v14.i6.215